26 jul: Statoil Q2: Dobbelt så godt som ventet
26 jul: Råvarer: Større lagre sender olieprisen på retur
26-07-2012 07:54:00

Sanofi Second-Quarter Net Profit up 16% Boosted by Tax Effect

Relateret indhold

By Noemie Bisserbe

PARIS--France's top drug maker Sanofi SA (SNY, SAN.FR) said Thursday it expected its earnings to fall this year, dented by the loss of patents on some of its blockbuster drugs, even as it posted a firm increase in second-quarter net profit, boosted by a tax effect.

The Paris-based pharmaceutical major said net profit attributable to shareholders rose 16% to 1.17 billion euros (US$1.4 billion) in the quarter ended June 30, from EUR1.01 billion a year earlier.

Business net income--the term it uses for adjusted income excluding items such as impacts associated with acquisitions and divestments--was, however, down 9.6% to EUR1.94 billion, hit by the loss of its patents on top-selling drugs--blood thinner Plavix and Avapro, a drug used to treat high blood pressure.

Analysts had forecast a second-quarter business net profit of EUR1.88 billion.

Sanofi's woes underscore drug makers' growing difficulty in keeping their heads above water as they swim from one blockbuster drug to another. On Wednesday, GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Co. (BMY) and Eli Lilly & Co. (LLY) reported sharp drops in second-quarter net profit, hit by a wave of patent expirations for top-selling drugs.

Sanofi maintained its full-year guidance for a 12% to 15% decline in business earnings per share in 2012, assuming no major changes in exchange rates.

Analysts, however, expect Sanofi's earnings to rebound from 2013, as the group strives to rely less on innovative drug sales.

Sanofi, which is struggling with patent expirations, has been extending its pharmaceutical business to growth areas such as emerging markets, vaccines, diabetes solutions, consumer health care, innovative products and animal health, in a bid to become less dependent on patented medicines.

Net sales rose 6.2% to EUR8.87 billion, with revenue at the flagship pharmaceutical division increasing 5.1% to EUR7.5 billion.

Write to Noemie Bisserbe at noemie.bisserbe@dowjones.com

Order free Annual Report for Sanofi

Visit http://djnweurope.ar.wilink.com/?ticker=US80105N1054 or call +44 (0)208 391 6028

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 01:54 ET (05:54 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

OPTAKT Vestas Q1 6/5: Opjustering kan være i vente

30-04-2015 15:20:41
Når Vestas onsdag aflægger regnskab for første kvartal, vil den primære fokus blandt analytikerne være rettet mod selskabets forventninger, som ved den lejlighe..

Novo/Schultz: Det tjener mine egne interesser at stoppe

30-04-2015 13:04:45
Det er i egen interesse, at Novos toer, Kåre Schultz, nu stopper som viceadministrerende direktør og ansvarlig for Novo Nordisks drift.Det siger han til Ritzau ..

Aktier/middag: DSV kører fra Danske Bank og Novo Nordisk

30-04-2015 11:32:44
Tranportkoncernen DSV varmer op til forlænget weekend og ligger i front i C20 Cap-indekset torsdag middag. Aktien stiger med 1,9 pct. til 224,30 kr. - og dermed..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Sanofi 91,20 -0,4% Fald i aktiekurs
Sanofi 51,29 1,5% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
3. maj 2015 14:55:55
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150424.2 - EUROWEB2 - 2015-05-03 14:55:55 - 2015-05-03 14:55:55 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x